A new report based on patient focus groups suggests many clinicians can do more to help patients with sickle cell disease (SCD) feel heard and understood. People with sickle cell disease (SCD) say a ...
The National Academies of Sciences, Engineering, and Medicine are private, nonprofit institutions that provide expert advice on some of the most pressing challenges facing the nation and world. Our ...
Sixteen patients dosed with Pfizer’s sickle cell disease drug Oxbryta® (voxelotor) in a pair of clinical trials have died, European regulators disclosed hours before Pfizer said it was voluntarily ...
The FDA has approved the first clustered regularly interspaced short palindromic repeats (CRISPR) gene-editing therapy for use in patients with sickle cell disease (SCD). Exagamglogene autotemcel (exa ...
Pfizer’s sickle cell disease (SCD) drug has flunked a key phase 3 test, the latest blow to the pharma’s $5.4 billion acquisition of Global Blood Therapeutics. Pfizer acquired the P-selectin inhibitor, ...
Chronic pain is the most common complication affecting adults with sickle cell disease (SCD). 1 Pain profoundly affects people’s quality of life, functional ability, and health care utilization.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback